Ainos, Inc. (AIMD)
| Market Cap | 6.13M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -13.77M |
| Shares Out | 5.95M |
| EPS (ttm) | -3.36 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 20,984 |
| Open | 1.020 |
| Previous Close | 1.030 |
| Day's Range | 1.010 - 1.030 |
| 52-Week Range | 0.790 - 6.100 |
| Beta | 1.47 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 10, 2024 |
About AIMD
Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based... [Read more]
Financial Performance
Financial StatementsNews
Ainos Reports Full Year 2023 Financial Results
Strategic pivot towards VELDONA and AI-powered point-of-care testing to continue in 2024 Advancing VELDONA drug candidates to Phase III clinical studies Expanding market of AI Nose-powered VOC-sensing...
Ainos Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation Against Mild COVID-19 Symptoms
Updated Chemistry, Manufacturing, and Controls and Stability Test fulfill Ainos' development objectives Resolving the identified deficiencies will accelerate the timeline for Ainos' other clinical tri...
Ainos Announces $1.75 Million Follow-On Funding
The follow-on funding is a draw down from the $10 million private placement agreement entered into September 25 2023. Use of proceeds include to advance planned VELDONA IND preparation and AI Nose VOC...
Ainos Regains Compliance with Nasdaq Minimum Bid Price Requirement
SAN DIEGO, CA / ACCESSWIRE / January 2, 2024 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of novel point-of-care testing,...
Ainos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-development Powered by AI Nose, Accelerating the Digitalization of Smell
Mass Production Readiness Targeted for 2H 2024 Propelling AI Nose Technology Towards Broader Industry Adoption and Advancing the Mission of Digitalizing Smell SAN DIEGO, CA / ACCESSWIRE / December 26,...
Ainos, Inc. Announces Stock Consolidation
SAN DIEGO, CA / ACCESSWIRE / December 12, 2023 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos," or the "Company"), a diversified healthcare company focused on the development of AI-powered point-of-care t...
Ainos Announces Successful Manufacturing of VELDONA GMP Clinical Batch by Swiss Pharmaceutical
Subsequent Phase Involves Completion of Chemistry, Manufacturing, and Controls (CMC) Information Ainos Intends to Submit Investigational New Drug Applications to the U.S. FDA for Multiple Candidates D...
Ainos Announces Positive Data Reported from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA
Data partially fulfills the safety and efficacy hypotheses of one pilot and two Phase II clinical studies Ainos aims to pursue a pre-IND meeting with the U.S. FDA ahead of a planned Phase III study SA...
Ainos Reports Third Quarter 2023 Financial Results
Product Cycle Transition Approaches its Final Stages New Product Line Expected to Gain Momentum in the Fourth Quarter SAN DIEGO, CA / ACCESSWIRE / November 9, 2023 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) (...
Ainos Signs MoU for Contract Clinical Trials to Conduct Clinical Study of Potential New Animal Drug Based on VELDONA
Ainos and SIDSCO will cooperate to accelerate the development of new animal drugs based on Ainos' VELDONA® low-dose oral interferon Upcoming clinical study will investigate VELDONA®'s safe use and eff...
Ainos Announces Placement of Initial $3 Million Tranche of $10 Million Private Placement
Proceeds to fund company's clinical trials, commercial product launch, and working capital Initial conversion price set at $1.50 per share SAN DIEGO, CA / ACCESSWIRE / September 25, 2023 / Ainos, Inc....
With Orphan Drug Designation, Ainos' VELDONA Has Compelling Opportunity to Improve Quality of Life for HIV Patients
Boston, Massachusetts--(Newsfile Corp. - September 19, 2023) - The U.S. Food and Drug Administration (FDA) has granted Ainos' (NASDAQ: AIMD) VELDONA Orphan Drug Designation (ODD) for the treatment of ...
Ainos' VELDONA Granted Orphan Drug Designation by U.S. FDA for Potential Treatment of Oral Warts in HIV-Seropositive Patients
VELDONA® positioned as a potential treatment option for over 24,000 HIV-seropositive Americans SAN DIEGO, CA / ACCESSWIRE / September 18, 2023 / Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Com...
Ainos Commences Shipping its VELDONA Pet Cytoprotein Supplements in Taiwan
First Batch of 300,000 Units to be Fully Delivered in October Ainos Has Expanded Distribution in Multiple Channels and Plans to Scale Up Capacity for Expected Strong Demand SAN DIEGO, CA / ACCESSWIRE ...
Ainos, Inc - The AI Nose "Knows" What's Inside Your Body and Beyond
Boston, Massachusetts--(Newsfile Corp. - August 15, 2023) - Here at Horizon Insights, we see two big trends right now in healthcare - the emergence of Artificial Intelligence, or AI platforms, and the...
Ainos Reports Second Quarter 2023 Financial Results
Strategic Focus Continues to Pivot from COVID to Pet Health and AI-powered Testing Launch of VELDONA® Pet Provides New Revenue Stream for Near-Term; Ainos Flora Remains on Horizon for 2024 SAN DIEGO, ...
Ainos Celebrates First Listing Anniversary on Nasdaq
Ainos reflects upon multiple business milestones following Nasdaq listing, as it diversifies its revenues and advances its product pipeline SAN DIEGO, CA / ACCESSWIRE / August 10, 2023 / Ainos, Inc. (...
Ainos Partners with Nisshinbo Micro Devices and Inabata to Co-Develop VOC Sensing Platform For Broader Industry Adoption
The Collaboration Signals Era of New Innovation for AI Nose Technology for Broader Industry Adoption With Partnership, Ainos Makes Progress Towards Mission of Digitizing Smell SAN DIEGO, CA / ACCESSWI...
Ainos Issues Mid-Year Business Update Letter to Shareholders
Company ramping up marketing of VELDONA® Pet and aiming to complete clinical trials in Taiwan of its flagship AI Nose-powered POCT by the end of 2023 Ainos sees VELDONA® Pet and AI Nose-powered POCT a...
Ainos Provides Insights Into Its AI Nose Technology
Ainos' AI-Powered Digital Nose Technology to Transform Telehealth and Point-of-Care Testing Clinical Trials of AI Nose-powered POCT to be Completed by the End of 2023, Positioning Ainos to Capitalize ...
Ainos Completes VELDONA Pet Line-Up by Launching New VELDONA Pet Shiny and Slim in Push Towards $20M Revenue Target
Five VELDONA® Pet products are now available New supplements will launch in Taiwan in July ahead of the planned international release, helping to maintain immunity for millions of pets Ainos sets its ...
Ainos Launches New VELDONA Pet Lohas and Soothing Health Supplements, Catalyzing Its Drive to $20M Sales Target
New products support pets' emotional health and allergic responses, hit market in Taiwan following successful launch of VELDONA® Pet Expanding VELDONA® Pet product line builds growth momentum toward U...
Ainos Launches VELDONA Pet Cytoprotein Health Supplement Targeting $20M in Sales
VELDONA® Pet will hit shelves in Taiwan in June, with launches in other regions to follow Multiple new VELDONA® Pet products set to launch as Ainos enters the growing global pet care market SAN DIEGO,...
Ainos Appoints Amanda Sung as New Chief Financial Officer
Current CFO Celia Wu announces her retirement and transition to consulting role Sung brings nearly two decades of public company audit and compliance experience with major international accounting fir...
Ainos Reports First Quarter 2023 Financial Results
Ainos continues its strategic transition away from marketing COVID test kits and further advances commercialization of its VELDONA® and VOC POCT technologies Strategic pivot is underpinned by Ainos' d...